Body Fat Reduction Market to Reach USD 15.3 Billion by 2035

According to analysts at Vantage Market Research, the Global Body Fat Reduction Market size is worth USD 7.92 Billion in 2024 and is projected to reach USD 15.3 Billion by 2035, growing at a CAGR (Compound Annual Growth Rate) of 8.6% from 2025 to 2035. Key trends of market include growing non-invasive procedures, laser-based treatments, cryolipolysis, radiofrequency devices, AI-driven body contouring, rising medical tourism, personalized treatments, home-use devices, and increasing demand for aesthetic wellness.

Market Overview

Body fat reduction operations are becoming increasingly popular because to shifting beauty standards and a desire for a well-toned figure. The emergence of wellness culture, which links body fat loss to general health, is also driving this trend, as people strive to improve their fitness outcomes. Furthermore, social media and celebrity endorsements have normalized these therapies, lowered stigma and making them more accessible to a broader audience. According to WHO in 2022, WHO is urging countries to do more to reverse this predictable and preventable health crisis. Around 800 million people worldwide were living with obesity, including over 670 million adults and at least 120 million children and adolescents, according to the statistics from 2016. This number is still increasing. WHO estimates that by 2025, approximately 167 million more people – adults and children – will become less healthy because they are overweight or obese.

Companies are focusing on introducing cutting-edge technologies such as advanced Cryolipolysis, high-intensity focused ultrasound (HIFU), and laser therapies, which offer enhanced precision, faster results, and minimal recovery time compared to traditional methods. The Integration of artificial intelligence (AI) into therapeutic devices enables personalized solutions adapted to particular body types, further distinguishing items in the body fat reduction market. Furthermore, innovations such as smart gadgets and wearable technology that track development and optimize outcomes are gaining popularity.

Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2

• In April 2023, Eli Lilly and Company announced  that tirzepatide (10 mg and 15 mg) achieved superior weight loss compared to placebo at 72 weeks of treatment in results from SURMOUNT-2. The study met both co-primary objectives and all key secondary objectives for tirzepatide compared to placebo for both estimandsi. Those taking tirzepatide lost up to 15.7% (34.4 lb. or 15.6 kg) of body weight for the efficacy estimandii. SURMOUNT-2 is the second global phase 3 clinical trial that evaluated the efficacy and safety of tirzepatide for chronic weight management. The trial evaluated 938 adult participants with obesity or overweight and type 2 diabetes

Key Takeaways from the Report

• North America dominated the market with 39.50% of market share in 2024. Market is driven by a combination of rising obesity rates, increasing aesthetic awareness, and the widespread availability of advanced fat reduction technologies
• Based on the Treatment Modality, the Non-Invasive Treatments category accounted for significant market share of 64.70% in 2024. The segment includes advanced fat-reduction treatments that do not require surgery
• In 2024, by Target Body Area, the Abdomen dominated the market share of 39.60%. It have a procedure that target abdominal fat, which is one of the most common and stubborn fat deposits in the body
• Based on the End User Industries, the Dermatology Clinics category accounted for significant market share of 33.40% in 2024. The increased incidence of obesity, along with greater aesthetic awareness and a desire for outpatient operations, has resulted in a major increase in demand for Market in clinics

Top Companies

• Allergan PLC
• Alma Lasers
• Apyx Medical Corporation
• Asclepion Laser Technologies GmbH
• Bausch Health Companies Inc.
• BTL Industries
• Cutera Inc
• Cynosure
• EndyMed Medical Ltd.
• Fotona
• Syneron Medical Ltd

Report Coverage

Our market research reports provide comprehensive insights that are essential for strategic decision-making. We cover all key aspects of the market, including dynamics such as drivers, restraints, opportunities, and challenges, alongside the latest industry trends. Our analysis includes an in-depth technology roadmap, product life cycle evaluation, and PESTLE analysis, ensuring a thorough understanding of the market environment. We also assess GDP growth outlooks, examine regional market landscapes, and evaluate the impact of major events like the COVID-19 pandemic. Additionally, our reports feature a detailed competitive landscape, including company market shares and profiles, providing actionable intelligence to empower your business strategies.

Latest News

AMGEN ANNOUNCES ROBUST WEIGHT LOSS WITH MARITIDE IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT AT 52 WEEKS IN A PHASE 2 STUDY

• In November 2024, Amgen announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide (maridebart cafraglutide, formerly AMG 133), an investigational antibody peptide conjugate subcutaneously administered monthly or less frequently. In people living with obesity or overweight without Type 2 diabetes, MariTide demonstrated up to ~20% average weight loss at week 52 without a weight loss plateau, indicating the potential for further weight loss beyond 52 weeks